Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial

Llombart Cussac, A.Prat, A.Perez-Garcia, J. M.Mateos, J.Pascual, T.Escriva-De-Romani, S.Stradella, A.Ruiz-Borrego, M.Bermejo De Las Heras, B.Keyaerts, M.Sampayo-Cordero, M.Malfettone, A.Cortes, R.Galvan, P.Cortes, J.Gebhart, G.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/27210enPredictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trialconference outputopen access10.1016/j.annonc.2020.03.0401569-8041http://www.annalsofoncology.org/article/S0923753420361196/pdf538879300090